NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today announced it raised $105 million in private funding, which will allow it to expand its immunosequencing research platform and clinical diagnostic products.

Viking Global Investors contributed $5 million to complete Adaptive Bio's Series C financing round and $100 million into its Series D round. Viking was the sole investor in the Series D financing and will take an observer seat on Adaptive Bio's board, Seattle-based Adaptive Bio said.

It has raised a total of $120 million, it added.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Jun
12
Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.